cannepil question and other questions, page-2

Hope these links help...

2018

	Column 1	Column 2	Column 3
0	26/02/2018 8:04 AM		Half Yearly Report and Accounts 27 pages 8.2MB
1	16/02/2018 3:54 PM		Exercise of 6.5c Listed Options - Appendix 3B 11 pages 901.8KB
2	14/02/2018 9:31 AM		MXC Derma Products Officially Launched on Cult Beauty Online 2 pages 551.7KB
3	09/02/2018 3:21 PM		Restricted Securities to be Released from Escrow 1 page 354.1KB
4	02/02/2018 11:53 AM		Cleansing Notice - s708A(5)(e) of the Corporations Act 2001 11 pages 915.0KB
5	31/01/2018 6:36 PM		December Quarterly Activity and Cashflow Report 10 pages 1.3MB
6	30/01/2018 1:14 PM		Appendix 3Y - Change of Director's Interest Notice x 3 6 pages 422.0KB
7	30/01/2018 1:12 PM		Conversion of Performance Rights - Appendix 3B 11 pages 905.1KB
8	25/01/2018 9:51 AM		Initial GMP Certification for European Production Facility 2 pages 566.1KB
9	23/01/2018 12:22 PM		Trading Halt 2 pages 617.6KB
10	22/01/2018 9:57 AM		MXC Signs Exclusive Distribution Agreement with Cult Beauty 2 pages 484.4KB
11	05/01/2018 10:09 AM		MXC Welcomes Federal Export Legislation 3 pages 394.8KB
12	04/01/2018 10:19 AM		MGC Derma Launches CBD Herbal Psoriasis Cream 2 pages 308.8KB
13	03/01/2018 4:48 PM		Response to ASX query 6 pages 762.1KB
14	02/01/2018 7:07 PM		Appointment of Joint Company Secretary 1 page 220.7KB

2017

	Column 1	Column 2	Column 3
0	18/12/2017 10:06 AM		MXC Operational Update 3 pages 510.1KB
1	15/12/2017 2:51 PM		Exercise of 6.5c Listed Options - Appendix 3B 11 pages 515.5KB
2	14/12/2017 10:02 AM		New Year Launch of MGC Derma CBD Psoriasis Cream Confirmed 2 pages 287.0KB
3	22/11/2017 7:25 PM		Results of Annual General Meeting 1 page 233.3KB
4	22/11/2017 9:51 AM		Binding Agreement to Supply $1m CBD Extract Annually 3 pages 238.4KB
5	20/11/2017 9:44 AM		Definitive Supply Agreement Executed with HL Pharma 3 pages 463.2KB
6	14/11/2017 10:39 AM		First Varm Cosmo Binding Purchase Order Received 2 pages 245.4KB
7	01/11/2017 9:41 AM		MXC Enters Multi $M Australian Pharma Market 3 pages 392.2KB
8	01/11/2017 8:17 AM		September Quarterly Activity and Cashflow Report 11 pages 1.5MB
9	30/10/2017 9:54 AM		First $8m Binding Cosmetics Sales Agreement Signed 3 pages 274.7KB
10	20/10/2017 9:38 AM		$40 Million White-Label CBD Cosmetics Agreement Executed 2 pages 268.2KB
11	13/10/2017 9:36 AM		MXC Botanic Division Operational Update 3 pages 1.7MB
12	12/10/2017 5:10 PM		Notice of Annual General Meeting/Proxy Form 24 pages 670.6KB
13	12/10/2017 5:03 PM		Appendix 4G and Corporate Governance Statement 20 pages 411.3KB
14	12/10/2017 5:01 PM		Annual Report 2017 76 pages 16.6MB
15	03/10/2017 10:05 AM		Major EU Pharma Supply Agreement Signed with Lenis 3 pages 316.3KB
16	20/09/2017 10:18 AM		Letter from the CEO 3 pages 320.7KB
17	30/08/2017 8:47 AM		Appendix 4E and Audited 2017 Financial Report 60 pages 1.6MB
18	23/08/2017 9:57 AM		RMIT and MGC Pharmaceuticals Sign Strategic Agreement 3 pages 253.5KB
19	01/08/2017 8:38 AM		June Quarterly Activity and Cashflow Report 11 pages 2.1MB
20	06/07/2017 4:07 PM		Appendix 3Y - Change of Director's Interest Notice 3 pages 154.7KB
21	03/07/2017 10:27 AM		Botanical Division Update - Europe and Australia 5 pages 3.9MB
22	30/06/2017 2:05 PM		Appendix 3B and Cleansing Statement 11 pages 519.7KB
23	30/06/2017 1:03 PM		Exercise of Options by MXC Board 2 pages 259.9KB
24	19/06/2017 10:18 AM		First European Distribution Deal Signed for API Products 3 pages 555.3KB
25	05/06/2017 9:59 AM		EU Medical Cannabis License Granted with Strategic Agreement 3 pages 689.4KB
26	01/06/2017 9:14 AM		Trading Halt 2 pages 265.7KB
27	22/05/2017 1:03 PM		Positive MGC Derma Clinical Test Results 3 pages 471.1KB
28	10/05/2017 4:49 PM		CEO Appointment 2 pages 262.9KB
29	02/05/2017 10:12 AM		Strategic Agreement Signed with RMIT 3 pages 280.4KB
30	01/05/2017 1:52 PM		Trading Halt 2 pages 460.3KB
31	01/05/2017 11:02 AM		New EU Sales Agreements Signed For MGC Derma 3 pages 502.2KB
32	28/04/2017 6:37 PM		March Quarterly Activity and Cashflow Report 11 pages 1.1MB
33	10/04/2017 9:39 AM		Successful MXC First Cannabinoid Production 4 pages 350.3KB
34	05/04/2017 12:24 PM		European API Extraction Facility Completed 3 pages 275.6KB
35	03/04/2017 5:28 PM		Exercise of 6.5c Listed Options - Appendix 3B 11 pages 323.1KB
36	03/04/2017 10:42 AM		CHZ: Chesser Executes Binding Term Seet to Acquire Highly 16 pages 1.7MB
37	27/03/2017 10:22 AM		Investor Presentation - March 2017 21 pages 1.4MB
38	23/03/2017 2:37 PM		Successful Completion of $10m Placement - Appendix 3B 13 pages 547.1KB
39	17/03/2017 7:12 PM		Exercise of Options - Appendix 3B 11 pages 524.9KB
40	17/03/2017 9:57 AM		Placement of $10m Closed Significantly Oversubscribed 2 pages 238.3KB
41	15/03/2017 9:29 AM		Trading Halt 2 pages 265.4KB
42	07/03/2017 6:52 PM		Conversion of Employee Performance Rights - Appendix 3B 11 pages 521.4KB
43	28/02/2017 2:32 PM		Half Yearly Report and Accounts 28 pages 890.3KB
44	23/02/2017 10:01 AM		Australian Legislation Changes Fast Track MXC 2 pages 257.5KB
45	20/02/2017 9:53 AM		Cannabinoid Extraction Facility On Target Q2 Production 4 pages 1.4MB
46	17/02/2017 6:48 PM		Release of Shares from Escrow - Appendix 3B 8 pages 399.5KB
47	14/02/2017 9:48 AM		Medical Cannabis Clinical Study Commencing 3 pages 288.7KB
48	09/02/2017 8:05 PM		Trading Halt 2 pages 508.7KB
49	07/02/2017 9:47 AM		Panax Acquisition Completed 4 pages 252.1KB
50	01/02/2017 8:25 AM		December Quarterly Activity and Cashflow Report 10 pages 615.5KB
51	25/01/2017 10:58 AM		Commencement of Dermatological Clinical Trials 2 pages 520.1KB
52	09/01/2017 9:53 AM		European CPNP Approval Granted for Derma Products 3 pages 465.0KB

2016

	Column 1	Column 2	Column 3
0	28/12/2016 8:06 AM		Appendix 3Y - Change of Director's Interest Notice 2 pages 200.1KB
1	23/12/2016 4:37 PM		Issue of Performance Rights - Appendix 3B 11 pages 383.1KB
2	22/12/2016 11:52 AM		MXC Operations Update 4 pages 734.3KB
3	15/12/2016 9:55 AM		New Panax Acquisition Agreement Signed, Settlement Imminent 4 pages 270.1KB
4	07/12/2016 1:23 PM		MXC Appoints ex Revlon Director to Fast Track Cosmetic Sales 3 pages 315.4KB
5	02/12/2016 11:28 AM		First Major European Sales and Revenue for MGC Derma Range 3 pages 288.6KB
6	29/11/2016 8:17 PM		Results of Annual General Meeting 1 page 128.5KB
7	10/11/2016 6:53 PM		Cleansing Prospectus Closed 1 page 135.7KB
8	10/11/2016 2:12 PM		Appendix 3B - Issue of Listed Options 12 pages 483.7KB
9	09/11/2016 4:22 PM		Cleansing Prospectus 32 pages 338.4KB
10	07/11/2016 10:06 AM		EU Registration Commenced for CBD Derma Product Sales 2 pages 187.2KB
11	27/10/2016 9:45 AM		September Quarter Activity and Cashflow Report 9 pages 321.6KB
12	26/10/2016 5:18 PM		Appendix 4G and Corporate Governance Statement 20 pages 410.5KB
13	26/10/2016 8:58 AM		Annual Report 2016 37 pages 1.9MB
14	25/10/2016 7:35 PM		Notice of Annual General Meeting/Proxy Form 23 pages 476.0KB
15	21/10/2016 1:56 PM		Appendix 3Y - Change of Director's Interest Notice x 3 7 pages 198.5KB
16	17/10/2016 7:44 PM		Issue of Performance Rights - Appendix 3B 12 pages 503.7KB
17	11/10/2016 9:39 AM		Listed Options now Quoted - ASX Code MXCOD 1 page 123.3KB
18	06/10/2016 1:40 PM		Issue of Listed Options from Capital Raisings - Appendix 3B 13 pages 527.1KB
19	29/09/2016 12:32 PM		Operations Update - Multiple Revenue Streams Imminent 3 pages 224.6KB
20	27/09/2016 7:20 PM		Results of General Meeting 1 page 138.0KB
21	21/09/2016 10:04 AM		New Med Cannabis White Paper Developed with Uni of Sydney 2 pages 212.7KB
22	07/09/2016 6:16 PM		Cleansing Prospectus Closed - No Shares Issued 1 page 125.2KB
23	06/09/2016 6:16 PM		Cleansing Prospectus 31 pages 346.1KB
24	01/09/2016 1:06 PM		Strategic Agreement signed with Epilepsy Action Australia 2 pages 600.7KB
25	30/08/2016 10:14 AM		Q&A with Nativ Segev, MGC Pharmaceuticals Managing Director 1 page 108.9KB
26	29/08/2016 1:29 PM		Appendix 4E and Audited 2016 Financial Report 69 pages 1.7MB
27	26/08/2016 5:46 PM		Notice of General Meeting/Proxy Form 28 pages 632.9KB
28	23/08/2016 11:50 AM		Psoriasis and Acne Tests Advancing Ahead of Product Launch 2 pages 169.4KB
29	12/08/2016 5:21 PM		Appendix 3B - Issue of Consultant Shares 12 pages 374.2KB
30	11/08/2016 9:56 AM		Sale of Lingokoto and Bouroubourou Gold Exploration Assets 1 page 108.6KB
31	28/07/2016 12:37 PM		June Quarterly Activity and Cashflow Report 10 pages 1.3MB
32	20/07/2016 12:38 PM		Q&A with Dr Ross Walker, MGC Pharmaceuticals Director 1 page 108.7KB
33	13/07/2016 10:02 AM		Leading Epilepsy Expert Joins MXC Strategic Advisory Board 3 pages 207.4KB
34	27/06/2016 9:31 AM		First Revenues Received from Californian Cosmetics Deal 2 pages 169.9KB
35	24/06/2016 5:39 PM		Resignation of Director - Appendix 3Z 3 pages 275.8KB
36	23/06/2016 6:24 PM		Appendix 3B - Option Conversion 8 pages 255.4KB
37	15/06/2016 11:29 AM		MXC's First Crops Planted at European CBD Production Farm 3 pages 1.2MB
38	31/05/2016 4:03 PM		Completion of Priority Offer Share Allotment - Appendix 3B 13 pages 469.0KB
39	30/05/2016 9:41 AM		Health Canada Approves MGC Derma CBD Cosmetics 2 pages 167.0KB
40	27/05/2016 6:05 PM		Appendix 3Y - Change of Director's Interest Notice 3 pages 195.5KB
41	27/05/2016 9:51 AM		Chairman's Update to Shareholders 2 pages 172.3KB
42	25/05/2016 9:22 AM		FDA Approval Granted and First US Distribution Deal Signed 2 pages 173.5KB
43	23/05/2016 9:38 AM		Trading Halt 2 pages 359.5KB
44	20/05/2016 9:29 AM		Shareholder Priority Offer Closed Early - Oversubscribed 1 page 107.1KB
45	16/05/2016 6:51 PM		Appendix 3B - Prospectus Priority Offer 12 pages 374.1KB
46	16/05/2016 5:56 PM		Prospectus - Priority Offer 40 pages 400.7KB
47	16/05/2016 11:39 AM		Investor Presentation - May 2016 21 pages 1.7MB
48	16/05/2016 10:06 AM		Form 605 - Notice of ceasing to be a substantial holder x 2 2 pages 150.1KB
49	12/05/2016 3:01 PM		Priority Offer Timetable - Update 2 pages 166.6KB
50	12/05/2016 12:18 PM		Completion and Allotment of Placement Shares 1 page 106.2KB
51	11/05/2016 7:08 PM		Appendix 3B Updated - Prospectus 12 pages 386.5KB
52	11/05/2016 6:54 PM		Supplementary Prospectus 10 pages 212.5KB
53	11/05/2016 3:37 PM		Appendix 3Y - Change of Director's Interest Notice 3 pages 196.0KB
54	11/05/2016 3:27 PM		Appendix 3B - Option Conversion 8 pages 254.3KB
55	11/05/2016 9:45 AM		European Commission Approves MGC Derma Cosmetics Products 2 pages 169.3KB
56	10/05/2016 9:36 AM		Reinstatement to Official Quotation 1 page 93.8KB
57	10/05/2016 9:36 AM		ASX Approval of Panax Transaction and Capital Raising Update 2 pages 174.0KB
58	09/05/2016 9:46 AM		Senegal Gold Assets - Project Status Update 1 page 106.2KB
59	04/05/2016 3:34 PM		Suspension from Official Quotation 1 page 257.4KB
60	04/05/2016 12:40 PM		Prospectus 39 pages 461.7KB
61	04/05/2016 9:48 AM		MXC to Raise $5.0m - Capital Raising Oversubscribed 3 pages 160.0KB
62	02/05/2016 10:11 AM		Response to ASX Aware Letter 5 pages 557.4KB
63	02/05/2016 9:25 AM		Trading Halt 2 pages 361.7KB
64	02/05/2016 8:16 AM		March Quarterly Activity and Cashflow Report 8 pages 284.3KB
65	27/04/2016 10:21 AM		MXC to Acquire Licensed European Medical Cannabis Company 4 pages 1.1MB
66	22/04/2016 9:55 AM		Trading Halt 2 pages 364.0KB
67	18/04/2016 7:31 PM		Response to ASX Price Query 4 pages 468.9KB
68	13/04/2016 10:30 AM		Launch of Online Store - First Retail Sales of CBD Cosmetics 2 pages 171.0KB
69	04/04/2016 11:14 AM		MXC to Enter Australian Medicinal Cannabis Market 3 pages 189.3KB
70	29/03/2016 9:36 AM		MXC Publishes First Australian Med Cannabis White Paper 3 pages 173.1KB
71	24/03/2016 11:12 AM		MXC Secures First Cosmetics Sales Agreement 2 pages 130.1KB
72	03/03/2016 9:19 AM		Agreement with SipNose takes MXC into Global Epilepsy Market 3 pages 264.5KB
73	29/02/2016 7:41 PM		Half Yearly Report and Accounts 25 pages 599.7KB
74	25/02/2016 10:03 AM		Legalisation of Medical Cannabis Fast Tracks Aus Opportunity 2 pages 151.2KB
75	23/02/2016 10:52 AM		Investor Report by the Next Bio Tech 1 page 93.0KB
76	23/02/2016 9:51 AM		Managing Director's Update to Shareholders 2 pages 134.7KB
77	19/02/2016 2:47 PM		Capital structure 1 page 93.9KB
78	19/02/2016 2:43 PM		Securities trading policy 13 pages 277.5KB
79	19/02/2016 2:40 PM		Pro forma balance sheet as at 31 January 2016 1 page 121.2KB
80	19/02/2016 2:40 PM		MGC Pharma (UK) Limited's account for 26/8/15 - 30/9/15 15 pages 1.2MB
81	19/02/2016 2:37 PM		Corporate governance statement 10 pages 224.8KB
82	19/02/2016 2:37 PM		Terms and conditions of Performance Shares 2 pages 126.6KB
83	19/02/2016 2:36 PM		Confirmations 1 page 105.0KB
84	19/02/2016 2:36 PM		Appendix 1A and Information Form and Checklist 18 pages 339.1KB
85	19/02/2016 2:35 PM		Constitution 67 pages 473.1KB
86	19/02/2016 2:35 PM		Distribution schedule & Top 20 Holders 1 page 107.7KB
87	19/02/2016 2:35 PM		Pre-reinstatement disclosure 1 page 260.6KB
88	19/02/2016 2:35 PM		ASX Notice - Reinstatement to Official Quotation 2 pages 283.0KB
89	19/02/2016 2:35 PM		Reinstatement to Official Quotation (23/02/2016) 1 page 257.0KB
90	17/02/2016 2:12 PM		Form 603 - Notice of initial substantial holder x 2 4 pages 156.4KB
91	17/02/2016 2:10 PM		Form 605 - Notice of ceasing to be a substantial holder x 2 3 pages 349.7KB
92	16/02/2016 6:19 PM		Appendix 3X - Initial Director's Interest Notice x 3 6 pages 179.2KB
93	16/02/2016 6:17 PM		Appendix 3Z - Final Director's Interest Notice 2 pages 166.2KB
94	16/02/2016 9:34 AM		Completion of Acquisition - Appendix 3B 13 pages 406.4KB
95	12/02/2016 12:32 PM		Managing Director's Update to Shareholders 2 pages 138.1KB
96	11/02/2016 7:23 PM		Supplementary Prospectus 4 pages 143.6KB
97	11/02/2016 7:22 PM		Issue of Supplementary Prospectus and Option Cancellation 1 page 97.1KB
98	11/02/2016 12:45 PM		MGC Welcomes Medical Cannabis Legislation Change 3 pages 161.5KB
99	01/02/2016 10:29 AM		December Quarterly Activity and Cashflow Report 9 pages 234.4KB
100	27/01/2016 11:16 AM		Conditional Reinstatement Letter Issued 1 page 81.7KB
101	04/01/2016 9:11 AM		Prospectus Offers Closed 1 page 87.8KB
102	04/01/2016 9:11 AM		App 3B Issue of July 15 Unlisted Options 12 pages 159.4KB